U.S. Markets open in 52 mins
  • S&P Futures

    4,163.50
    +1.00 (+0.02%)
     
  • Dow Futures

    33,933.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    14,014.25
    +0.25 (+0.00%)
     
  • Russell 2000 Futures

    2,257.20
    +1.50 (+0.07%)
     
  • Crude Oil

    63.37
    -0.09 (-0.14%)
     
  • Gold

    1,764.90
    -1.90 (-0.11%)
     
  • Silver

    25.92
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1973
    -0.0003 (-0.0240%)
     
  • 10-Yr Bond

    1.5300
    -0.1080 (-6.59%)
     
  • Vix

    16.57
    -0.42 (-2.47%)
     
  • GBP/USD

    1.3784
    -0.0001 (-0.0041%)
     
  • USD/JPY

    108.6920
    -0.0240 (-0.0221%)
     
  • BTC-USD

    61,105.07
    -1,327.91 (-2.13%)
     
  • CMC Crypto 200

    1,397.85
    +16.90 (+1.22%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,642.69
    +21.70 (+0.07%)
     

Adamis Pharma Shares Fall Despite US Patent Covering Naloxone

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • U.S. Patent and Trademark Office has allowed a patent to one of the patent applications by Adamis Pharmaceuticals Corp (NASDAQ: ADMP) related to its ZIMHI high-dose naloxone injection product candidate, intended for opioid overdose.

  • The allowed claims comprise a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection.

  • "Our 5 mg dose of naloxone delivered by intramuscular or subcutaneous injection has demonstrated significantly higher availability (naloxone in the blood) at 2.5 and 5 minutes (critical period) when compared to the current FDA-approved product", said Dr. Dennis J. Carlo, President, and CEO.

  • Last year, the company received an FDA response letter for the ZIMHI application for opioid overdose, citing Chemistry, Manufacturing, and Controls issues.

  • The company says it looks forward to meeting with the FDA to discuss the responses submitted to the agency's response letter for ZIMHI.

  • Price Action: ADMP stock is down 7.01% at $1.46 in market trading hours on last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.